| الوصف: |
Aims Small invasive carcinomas arising in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas can present as multiple, small foci. In such cases, there is no clear optimal measurement method for determining the invasive size for tumour staging and prognostication. Methods In all, 117 small invasive IPMNs (size of largest invasive component ≤2 cm) from seven institutions (2000–2016) were reviewed, and all individual foci of invasive carcinoma were measured. T stages (AJCC 8th edition) based on the largest single focus size (LS), average size of all foci (AS), and total sum of all foci (TS) were examined in association with clinicopathologic parameters and patient outcomes. Results The cohort comprised IPMNs with invasive tubular‐type ( n = 82, 70%) and colloid‐type ( n = 35, 30%) carcinomas. The mean LS, AS, and TS were 0.86, 0.71, and 1.32 cm, respectively. Based on the LS, AS, and TS, respectively, 48, 65, and 39 cases were classified as pT1a; 22, 18, and 11 cases as pT1b; and 47, 34, and 50 cases as pT1c. Higher pT stages based on all measurements were significantly associated with small vessel, large vessel, and perineural invasion ( P < 0.05). LS‐, AS‐, and TS‐based pT stages were not significantly associated with recurrence‐free survival (RFS) or overall survival (OS) by univariate or multivariate analyses. However, among tubular‐type carcinomas, higher LS‐, AS‐, and TS‐based pT stages trended with lower RFS (based on 1‐, 3‐, and 5‐year survival rates). All microscopic measurement methods were most predictive of RFS and OS using a 1.5‐cm cutoff, with LS significantly associated with both RFS and OS by univariate and multivariate analysis. Conclusions For invasive tubular‐type carcinomas arising in IPMN, microscopic size‐based AJCC pT stages were not significant predictors of patient outcomes. However, for LS, a size threshold of 1.5 cm was optimal for stratifying both RFS and OS. The AJCC 8th ed. may not be applicable for stratifying small invasive IPMNs with colloid‐type histology that ... |
